PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|October 22, 2013
CPhI Announces Finalists for Pharma Awards
Author(s)Pharmaceutical Technology Editors
Winners for the 2013 CPhI Pharma Awards, which recognize pharmaceutical innovation, will be awarded on later today, Tuesday Oct. 22.
Advertisement
As CPhI Worldwide kicks off this week in Frankfurt, the finalists for the CPhI Pharma Awards have been released. The winners will be announced at a special awards ceremony at CPhI on Tuesday Oct. 22. CPhI is recognizing innovation in three categories: process development, formulation, and packaging.
Three finalists are up for the Best Innovation in Process Development. They include: API Corporation (Tokyo) for a practical synthesis of functionalized pharmaceuticals through carbon–hydrogen activation; Bachem (Bubendorf, Switzerland) for a chemical synthesis of interferon beta-1a; and Codexis (Redwood City, California) for green and scaleable biocatalytic oxidations.
Three finalists are competing for the Best Innovation in Formulation. They include: Bitop AG (Witten, Germany) for Ectoin, a proprietary ingredient derived from an amino acid found in extremophilic microorganisms and which has cell-protective properties that can be used in medical devices, life-science products, and cosmetics; Camurus (Lund, Switzerland) for FluidCrystal, a proprietary injection depot and related technology; and EmulTech BV (Eindhoven, the Netherlands) for its microfluidic platform and technology.
The three finalists for the Best Innovation in Packaging are: E-Pharma Trento (Trento, Italy), which specializes in niche oral delivery soluble forms, for a three-layer blister pack designed to protect fragile dosage forms such as orally disintegrating tablets; Doctor Pack India (Bangalore, India) for MAGIC CAP, which allows for sterile piercing and precise dosage for drops; and Neutroplast (Sobral Monte Agraço, Portugal) for a vaginal applicator.
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement